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Many mast cell-associated diseases, including allergies and asthma, have seen a strong 
increase in prevalence during the past decades, especially in Western(ized) countries. 
It  has been suggested that a Western diet may contribute to the prevalence and
 manifestation of allergies and asthma through reduced intake of dietary fiber and the 
subsequent production of their metabolites. Indeed, dietary fiber and its metabolites have 
been shown to positively influence the development of immune disorders via changes 
in microbiota composition and the regulation of B- and T-cell activation. However, the 
effects of these dietary components on the activation of mast cells, key effector cells of 
the inflammatory response in allergies and asthma, remain poorly characterized. Due to 
their location in the gut and vascularized tissues, mast cells are exposed to high con-
centrations of dietary fiber and/or its metabolites. Here, we provide a focused overview 
of current findings regarding the direct effects of dietary fiber and its various metabolites 
on the regulation of mast cell activity and the pathophysiology of mast cell-associated 
diseases.
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iNTRODUCTiON
Western diets are characterized by the consumption of energy-rich foods and beverages, typically 
high in fat, sugar, and salt but low in dietary fiber. These diets have been shown to affect the immune 
system and are thought to promote the development of a variety of immune disorders, including 
allergies and asthma (1, 2). Indeed, the past decades have seen a strong increase in the prevalence of 
allergic diseases in developed countries with a Western lifestyle, parallel to a reduced consumption 
of dietary fiber (3). Immune disorders that are thought to be most affected by the change in dietary 
fiber intake include asthma, eczema, hay fever, and food allergy (4, 5). A recent example comes from 
the reunification of East and West Germany, after which a significant increase in the prevalence of 
childhood hay fever and allergic sensitization was reported in East Germany, following exposure 
to several years of Western living conditions (6). Intriguingly, disorders that are most affected by 
reduced fiber consumption are often strongly linked to mast cell activity (3). However, most of the 
research regarding the effects of Western diet on such disorders has primarily focused on disease 
initiation via B and T-cell activation, rather than disease manifestation itself. Hence, the effects of 
dietary fiber and its metabolites on mast cells and other effector cells of allergy and asthma remain 
poorly understood.
TAble 1 | Constituents of dietary fiber.a
Non-starch polysaccharides and resistant oligosaccharides
Cellulose
Hemicellulose
Arabinoxylans
Arabinogalactans
Polyfructoses
Inulin
Oligofructans [fructo-oligosaccharides (FOS)]
Galacto-oligosaccharides (GOS)
Gums
Mucilages
Pectins
Analogous carbohydrates
Indigestible dextrins
Resistant maltodextrins (from corn and other sources)
Resistant potato dextrins
Synthesized carbohydrate compounds
Polydextrose
Methyl cellulose
Hydroxypropylmethyl cellulose
Indigestible (“resistant”) starches
lignin-substances associated with the non-starch polysaccharide and 
lignin complex in plants
Waxes
Phytate
Cutin
Saponins
Suberin
Tannins
aDietary fiber components as defined by the American Association of Cereal Chemists. 
Adopted from “The Definition of Dietary Fiber” (15).
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Dietary fiber consists of non-digestible carbohydrates sourced 
from plant polysaccharides and plant or human milk-derived 
oligosaccharides. They are resistant to enzymatic and chemical 
digestion until they reach the large intestine, where they are fer-
mented to short-chain fatty acids (SCFAs) and other metabolites 
by gut bacteria (7). Mammals, including humans, are deficient in 
the enzymes required to degrade the bulk of polysaccharides and 
resistant oligosaccharides, as illustrated by decreased amounts 
of SCFAs in germ-free mice, which lack bacteria in the gut (8). 
A high-fat/low-fiber diet is accompanied by an increase in the 
Firmicutes/Bacteroidetes species ratio, which is associated with 
different disease types, including obesity (9). In contrast, a high-
fiber diet leads to an increased Bacteroidetes to Firmicutes ratio 
and elevated concentrations of SCFAs (10, 11). The potential 
role of gut microbiota in allergic diseases and asthma has been 
well documented and extensively reviewed (12–14). Here, we 
will provide a focused overview of the current findings regard-
ing the direct effects of dietary fiber and its metabolites on the 
regulation of mast cell activity and the pathophysiology of mast 
cell-associated diseases.
DieTARY FibeR—iTS SOURCe, 
MeTAbOliSM, AND biOlOGiCAl iMPACT
In contrast to starch and starch-like polysaccharides that are 
 easily hydrolyzed by enzymatic reactions and absorbed in the 
small intestine, dietary fiber is neither digested nor absorbed 
until after bacterial fermentation in the large intestine. Defining 
and categorizing dietary fiber is complex and challenging due 
to a large variety in their nutritional, functional, and chemical 
properties. The American Association of Cereal Chemists defines 
dietary fiber as “carbohydrate polymers with more than a three-
degree polymerization, which are neither digested nor absorbed 
in the small intestine” (15) (Table  1). However, this definition 
incorporates a great variety of fiber. In the field of (allergic) 
inflammation and immunology non-starch polysaccharides 
(mainly found in vegetables, fruits, and cereals), oligosaccharides 
(primarily found in plants, beans, and human milk), together 
with specific analogous carbohydrates, such as resistant starch, 
recently received particular attention. Therefore, we will focus on 
the effects of these dietary fiber components and its metabolites. 
The role of other dietary fiber components and metabolites on the 
immune system has been reviewed elsewhere (16–18).
Both polysaccharides and resistant oligosaccharides are potent 
substrates for the production of SCFAs. SCFAs are known to exert 
their biological effects through activation of membrane receptors 
GPR41, GPR43, and GPR103 (19–21), as well as the peroxisome 
proliferator-activated receptor (PPAR) nuclear receptor family 
(22). PPARs function as transcription factors, following the for-
mation of a heterodimer with the retinoid X receptor, and regulate 
the expression of genes that are involved in both metabolism and 
immunity (23). SCFAs also possess the capacity to inhibit histone 
deacetylase (HDAC) activity (24–26), which is known to regulate 
gene expression, as well as the acetylation of non-histone proteins, 
including transcription factors (27). Acetate, propionate, and 
butyrate are the most extensively described SCFAs and are found 
in the intestinal tract at a molar ratio of 60:20:20, respectively (28). 
Importantly, SCFAs are not restricted to the intestinal tract, but 
can disseminate systemically and are detectable in the blood (29).
eFFeCTS OF DieTARY FibeR AND iTS 
MeTAbOliTeS ON MAST Cell FUNCTiON
Mast cells play a central role in initiating and maintaining inflam-
mation, particularly in allergies and asthma (30). Although mast 
cells can be found in all well vascularized tissues, they are pre-
dominantly found in tissues where our body makes contact with 
the outside world (31). These tissues include the gastrointestinal 
tract (GI), the upper and lower airways, and the skin. The local 
or systemic presence of plasma-cell derived immunoglobulin E 
(IgE) can prime mast cells via the high affinity receptor FcεRI (30). 
Re-exposure to a specific allergen induces FcεRI aggregation on 
the plasma membrane, which can trigger mast cell degranulation 
within minutes, releasing numerous inflammatory mediators, 
such as serine proteases (tryptase and chymase) and histamine 
(32). Subsequently, downstream signals initiate the transcription 
and secretion of many pro-inflammatory cytokines, including 
TNF (33, 34) and IL-6 (35). Although the complete sequence of 
events that leads up to mast cell activation is not fully understood, 
it is known that aggregation of FcεRI results in the phosphoryla-
tion of the linker for activation of T cells (LAT) adaptor molecule 
in a LYN and SYK (spleen tyrosine kinase) dependent manner (36) 
(Figure 1). This sequence of signaling events subsequently causes 
FiGURe 1 | Inhibition of mast cell activation by dietary fiber and butyrate. Mast cell activation is modulated by dietary fiber and butyrate via (1) a reduced calcium 
entry, (2) inhibition on JKN/p38 phosphorylation, (3) reduced histone deacetylase (HDAC) activity, and (4) regulation of p65, AP-1, NFAT activity. Partly adopted from 
Cildir et al. (40).
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activation of PLCγ and protein kinase C (PKC), which increases 
the mobilization of calcium (Ca2+) to initiate mast cell degranula-
tion (36). On the other hand, de novo synthesis of eicosanoids 
(such as leukotrienes and prostaglandins) and transcriptional 
activation of cytokine genes (including TNF and IL-6) are induced 
by the activation of the mitogen-activated protein kinase (MAPK) 
pathway. Activation of the MAPK proteins extracellular signal-
regulated kinase 1 (ERK1) and ERK2 are known to be regulated by 
RAS/RAF complex and play a major role in cell differentiation and 
proliferation (37). MAPK kinases (MAPKKs) and the MAPKK 
kinases (MAPKKKs) that mediate activation of p38 and c-Jun 
N-terminal kinase (JNK) in mast cells are less well-defined (38, 
39), but are generally associated with apoptosis and inflammation.
Mast cell activation can also be induced by many IgE-
independent stimuli, such as neurotransmitter substance P or 
complement anaphylatoxins (e.g., C3a and C5a) (22). Interest-
ingly, different mast cell activators can induce cell activation 
using different types of degranulation strategies (41). However, 
the involvement of the MAPK signaling pathway in mast cell 
activation seems to be preserved regardless of the nature of 
the stimulus (38, 42, 43). Importantly, both MAPKs as well as 
a Ca2+ influx strongly regulate transcription of cytokines via 
transcription factors, such as NF-κB, NFAT, and AP-1 (40). 
For example, the nuclear localization (and, therefore, effective 
DNA binding) of NFAT transcription factors is controlled by 
an interplay of Ca2+ signaling with other signaling pathways 
(e.g., MAPK) (44). Second, various transcription factors normally 
reside in the cytosol, and make their passage into the nucleus 
through the nuclear envelope via nuclear pore complexes (NPC) 
to reach the chromatin. Increases in cellular Ca2+ (45) and MAPK-
induced phosphorylation of certain compartments of the NPC 
(e.g., nucleoporins) (37) can regulate the nuclear translocation 
of these transcription factors. Finally, nuclear MAPKs have been 
shown to directly regulate chromatin remodeling, thereby modu-
lating DNA accessibility (37). Erk1/2 was reported to interact with 
and phosphorylate HDAC4 in vitro (46). Additionally, activation 
of the ERK1/2 pathway induces the translocation of HDAC4 into 
the nucleus, thereby potentially regulating chromatin state.
Although the effects of dietary fiber have been investigated 
extensively in disease that are associated with mast cell activation, 
there have been few published reports demonstrating its effects 
on mast cell activation and function. A recent study has shown 
that Angelica polysaccharide (AP), a major source of fiber from 
the medicinal herb Angelica, can inhibit mast cell histamine 
release in a dose-dependent fashion as well as mediator synthesis 
via reduced Ca2+ entry, p38 phosphorylation, and NF-κB p65 
expression (47). Additional studies have supported these find-
ings by demonstrating that both polysaccharides (48, 49) and 
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oligosaccharides (50) can directly inhibit mast cell degranulation 
and pro-inflammatory cytokine production in vitro.
In contrast, the effects of microbial metabolites, SCFAs, on 
mast cell function have been studied in more detail. In an early 
report, Galli et al. showed that MC/9 mouse mast cells exhibited 
decreased cell proliferation and increased histamine content and 
cytoplasmic granules when exposed to butyrate in  vitro (51). 
Recently, Diakos and colleagues (52) were the first to report that 
butyrate can inhibit mast cell degranulation and TNF production. 
Butyrate administration significantly inhibited the phosphoryla-
tion of JNK, but not Erk1/2 and p38, thereby potentially regu-
lating mast cell activation and TNF production. Production of 
TNF following IgE-dependent mast cell stimulation is known to 
be strongly regulated at the level of gene transcription (53, 54). 
Therefore, the authors assessed the binding of different transcrip-
tion factors in the TNF promoter region and found that butyrate 
significantly inhibited nuclear binding of AP-1 and NF-AT.
The effects of butyrate on mast cell degranulation were more 
recently confirmed by Wang et  al. (55), who demonstrated 
that sodium butyrate pretreatment reduced the percentage of 
degranulated mast cells, decreased mast cell mediator content, 
and lowered mRNA expression of pro-inflammatory cytokines 
in jejunal mucosa preparations isolated from weaned pigs. In line 
with a previous report (52), this study also found that butyrate 
affected the MAPK signaling pathway by inhibiting the phospho-
rylation of JNK, but not of Erk1/2 and p38.
However, a recent report by Zhang et al. showed that butyrate 
inhibited FcεRI-dependent release of TNF and IL-6 from mouse 
bone marrow-derived mast cells (BMMCs) without affecting 
degranulation (56). Moreover, butyrate pretreatment decreased 
c-Kit expression of mouse mastocytoma P815 cells and sup-
pressed their cell proliferation by inducing cell cycle arrest and 
apoptosis. Furthermore, the transcriptional activity of TNF and 
IL-6 in antigen-stimulated BMMCs, was inhibited by butyrate 
as well as trichostatin A (TSA), a known HDAC inhibitor (56). 
Paradoxically, the authors also showed that butyrate-induced 
inhibition of HDAC activity leads to increased histone (H3K9) 
acetylation at the promotor regions of the TNF and IL6 genes 
(56)—a chromatin state strongly linked to gene activation (57, 58). 
As the increased histone acetylation of the chromatin is unlikely 
to explain the decreased cytokine transcription, butyrate exposure 
appears to suppress inflammatory cytokine expression via chro-
matin acetylation of upstream regulator genes (i.e., repressors of 
TNF and IL-6 transcription) or non-histone protein acetylation. 
Although less well studied than histone acetylation, many non-
histone proteins (including transcription factors) are subjected 
to acetylation, impacting numerous nuclear and cytoplasmic 
processes (59, 60). Butyrate and other dietary components with 
HDAC inhibiting activity have been reported to be key facilitators 
in non-histone protein acetylation (61). To explain the contradic-
tory effects found on acetylation of the histones, Zhang et al. also 
assessed butyrate-induced acetylation of α-tubulin in mast cells 
(56), which is controlled by the tubulin-associated HDAC6 (62). 
Butyrate inhibits most of the classic HDACs but not HDAC6 
and HDAC10 (63). As was to be expected, their study did not 
show any effects of butyrate on the acetylation of α-tubulin (56). 
Further research is needed to understand butyrate-induced 
non-histone acetylation in mast cells and its biological conse-
quences. Interestingly, the MAPK signaling pathway seems to 
react to changes in HDAC as phosphorylation of JNK, p38, and 
ERK1/2 was significantly inhibited in activated mast cells by both 
butyrate and TSA administration (56).
In summary, in  vitro studies have suggested that both dietary 
fiber and its metabolites may regulate mast cell-associated diseases 
via their major inhibitory effects on mast cell activation and 
degranulation (Figure 1). Limited data provided by a few published 
studies have further suggested that some of these effects appear to 
be mediated via inhibition of the MAPK signaling pathway and 
reduced TF activity, which are known to modulate mast cell function. 
Further detailed investigations of the mechanisms by which butyrate 
inhibits mast cell activation are warranted as an important reference 
for interpreting the outcome of studies investigating the effects of 
dietary fiber and metabolites in mast cell-associated diseases.
DieTARY FibeR iNTeRACTiONS wiTH 
GASTROiNTeSTiNAl MAST CellS
The GI is the primary organ to interact with dietary fiber. Although 
dietary fiber can, by definition, not be fermented before entering the 
large intestine, it exerts health benefits in the GI tract by regulating 
stool viscosity and increasing stool bulk. Patients with food aller-
gies may also benefit from high-fiber concentrations in the small 
intestine, as pectin-rich fruits hamper allergen digestion by pepsin 
in vivo and in vitro, thus regulating allergic sensitization in atopic 
individuals (64). Most of the beneficial effects of dietary fiber on (GI) 
health, however, come from colon-derived microbial metabolites.
Throughout the GI tract, substantial quantities of mast cells 
are strategically positioned in the mucosa and submucosa (65). 
Therefore, their role as mediators of GI diseases, such as food 
allergy, has been well documented, and they have been proposed to 
contribute to the pathology of certain forms of colitis and Crohn’s 
disease (66–68). Indeed, intestinal mast cells can strongly regulate 
blood flow, smooth muscle contraction, GI barrier function, as 
well as the initiation of (allergic) inflammation (69). Moreover, 
mucosal type mast cell (a tryptase positive, chymase negative 
subtype) numbers may increase in certain types of (allergic) GI 
inflammation, whereas numbers of connective tissue type mast 
cells (a tryptase/chymase double positive mast cell subtype) are 
more stable (65, 70, 71). Due to their location in the gut, mast cells 
are under the influence of high concentrations of dietary fiber and 
its metabolites. Interestingly, the effects of high-fiber diets on these 
mast cell-associated diseases have been well documented and offer a 
promising future avenue for intervention (72, 73). Moreover, some 
direct effects of dietary fiber and metabolites on intestinal mast cell 
activation in these diseases have been reported as described below.
Food Allergy
Reactions to food allergens are typically the result of intestinal mast 
cell activation and degranulation through food-specific IgE antibod-
ies (30, 74). Symptoms related to food allergy can range in severity 
between mild (e.g., hives, abdominal pain, diarrhea, and wheezing) 
to life threatening (e.g., anaphylaxis). A recent study, in which more 
than 300,000 children participated, showed that the prevalence of 
food allergy in the US is 6.7%, with the most common food allergens 
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being peanut (2.6%), milk (2.2%), egg (1.8%), shellfish (1.5%), and 
soy (0.7%) (75). On a global scale, the prevalence of food allergy is 
increasing, linked to industrialization and improved living condi-
tions (76, 77). Strict allergen avoidance and oral immunotherapy 
remain common strategies to prevent food-dependent allergic 
reactions. Recently, the utilization of dietary fiber and its metabo-
lites in the prevention or treatment of food allergies has received 
a lot of interest. Hogenkamp and colleagues (78) found impaired 
sensitization and attenuated allergic symptoms in the offspring of 
mice supplemented with dietary fiber, i.e., galacto-oligosaccharides 
(GOS), fructo-oligosaccharides (FOS), and pectin-derived acidic 
oligosaccharides. This suggests that dietary fiber can have signifi-
cant effects on the development of food allergy in mice, even in the 
offspring of animals on high-fiber diets.
Several recent studies have provided insights into the mecha-
nisms of action of dietary fiber and metabolites in allergic mice and 
humans. Tan et al. (79) reported that a high-fiber diet (enriched 
in guar gum and cellulose) protected mice against peanut allergy 
via altered gut microbiota and SCFA production. Anaphylaxis 
scores and IgE concentrations were decreased in mice fed with a 
high-fiber diet. However, whether this resulted in decreased mast 
cell activation was not reported. Interestingly, similar results were 
obtained by adding acetate or butyrate, but not propionate, to the 
drinking water for 3 weeks prior to allergen sensitization. These 
findings suggest that high-fiber diets can exert significant immu-
noregulatory effects though SCFA production. In a similar study 
by Kivit and colleagues (80), mice were fed prebiotic short-chain 
galacto- and FOS (scGOS/lcFOS, resembling the non-digestible 
oligosaccharides in human milk) and were orally sensitized to 
whey, a common food allergen. These mice displayed reduced 
acute hypersensitivity responses to the allergen, as measured 
by ear swelling, as well as serum mucosal mast cell protease-1 
(mMCP-1) levels, both markers for mast cell degranulation.
However, in such studies diets are usually given for weeks 
before allergen sensitization. Their effects on allergic inflamma-
tion are, therefore, often attributed to beneficial immunoregula-
tory effects on sensitization and allergy development, rather than 
on the inflammatory response in established allergic diseases. 
Nonetheless, Kivit and colleagues (80) showed that scGOS/
lcFOS diets upregulated galactin-9 levels in mice allergic to 
whey. Galactin-9 is a potent inhibitor of mast cell degranulation 
through blocking IgE–antigen complex formation (81), and high 
serum levels of galactin-9 are reportedly linked to a reduction of 
allergic inflammation and mast cell degranulation in vivo (80).
Ingestion of seaweeds commonly consumed in (Southeast) 
Asia are a rich source of polysaccharides (82), containing 
33–50% more fiber than the higher plants commonly consumed 
in the West (Marine Algae Extracts: Processes, Products, and 
Applications, 2). Extracts of sulfated polysaccharides from sea-
weed have recently been shown to directly regulate food allergy 
symptoms via effects on mast cell activation in vivo and in vitro. 
Ngatu et al. (48) showed inhibition of β-hexosaminidase release 
in rat basophilic leukemia RBL-2H3 cells by sulfated polysac-
charides. Xu et  al. (49) extended these findings by reporting 
that Eucheuma cottonii-derived sulfated oligosaccharides (ESO) 
protected mice from food allergy and anaphylaxis symptoms in 
both a preventive manner as well as therapeutic manner when 
ESO was administered after initial food challenges. Serum con-
centrations of histamine, mMCP-1, and food allergen-specific IgE 
were all reduced in mice treated with a high-fiber diet. In vitro 
measurements showed that mast cell degranulation and cytokine 
production were inhibited by the sulfated oligosaccharides in a 
dose-dependent manner (49). These results complement earlier 
findings by the same group showing that sulfated polysaccharide 
from Gracilaria lemaneiformis had similar effects on food allergy 
symptoms in mice, as well as mast cell activation, although 
these effects were more modest (83). In their study, Castillo-
Courtade and colleagues (50) tested the effects of two human 
milk oligosaccharides (HMOs) on immune responses in an 
ovalbumin-sensitized mouse model of food allergy. Both HMOs 
reduced diarrhea and hypothermia, as well as serum mMCP-1 
concentrations in mice with food allergy. One of the HMOs, 
6′-sialyllactose, was able to directly inhibit in  vitro mast cell 
degranulation. Together, these studies suggest that dietary fiber, 
especially oligosaccharides and polysaccharides, may regulate 
food allergy symptoms in part directly via inhibition of mast cell 
activation—a potentially important finding for patients with food 
allergies. Food allergies are typically characterized by mast cell-
induced intestinal mucosal permeability and inflammation of the 
ileum (84). Yet, the small intestine might miss out on much of the 
health benefits of high dietary metabolite concentrations, since 
they are primarily produced in the large intestine. Nonetheless, 
these studies show direct immunoregulatory effects of dietary 
fiber on mast cell function, thereby potentially influencing gut 
homeostasis in the small intestine as well.
Metabolites of dietary fiber have, justifiably, received significant 
attention in the search for possible explanations for the health 
benefits of dietary fiber. In addition to the indirect effects of dietary 
fiber (i.e., after fermentation in the large intestine, including upreg-
ulation of galactin-9 and SCFA production), fiber can have direct 
(i.e., prior to microbial fermentation) immunoregulatory effects 
on food allergy and mast cell activation. Thus, studies investigating 
the effects of dietary fiber on the onset and manifestation of allergies 
and other mast cell-associated diseases have to take into account 
that dietary fiber can directly influence immune responses, hereby 
regulating mast cell activation without intermediate factors.
inflammatory bowel Disease
The inflammatory bowel diseases, ulcerative colitis (UC) and 
Crohn’s disease (CD), are characterized by chronic inflamma-
tion of the GI tract. Prevalence and incidence have stabilized in 
developed countries, but are increasing in newly industrialized 
countries (85), in a similar manner to atopic diseases. In UC, 
inflammation is initiated and maintained by an atypical Th2 
response mediated by non-classical NKT cells. Typically, inflam-
mation in UC occurs between the rectum and cecum, where the 
gut is exposed to high concentrations of metabolites of dietary 
fiber (86). CD on the other hand is thought to be triggered by an 
imbalance between Th1, Th17 cells, and Tregs, which initiates a 
mucosal inflammation that can occur throughout the GI tract 
(87). Although T cell subsets play a central role in the develop-
ment of IBD, evidence indicating an important role of mast cells 
in the manifestation of IBD is accumulating (88, 89). In patients 
with UC or CD, histological and immuno-histochemical methods 
6Folkerts et al. Dietary Fiber Regulates Mast Cell Function
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1067
revealed mast cell degranulation in biopsies from inflamed tissue 
(90). Furthermore, mast cell numbers may be increased in fibrotic 
tissue of patients with CD (91), suggesting a functional role for 
mast cells in the pathogenesis of IBD. Indeed, mast cell expres-
sion of TNF, IL-16, and substance P, as well as histamine and 
tryptase levels were elevated in the mucosa of IBD patients (78). 
The contribution of mast cells to gut inflammation was further 
demonstrated in mast cell-deficient rats, which have significantly 
reduced microscopic mucosal damage in a DSS-induced colitis 
model (79). In wild type rats, mast cell counts correlated with 
local mucosal damage.
Nonetheless, direct activators of mast cells in IBD are not well 
defined, with currently no evidence indicating involvement of 
IgE-dependent mast cell activation. However, psychological stress, 
a known contributor to inflammation in IBD, caused significantly 
higher mast cell degranulation in patients with IBD (92). Indeed, 
corticotropin-releasing factor, a hormone known to be released in 
response to stress, increased intestinal paracellular permeability 
and gut inflammation via mast cell-dependent release of TNF and 
proteases (93). Finally, mast cells may exacerbate the symptoms of 
IBD following Ig-free L chain (Ig-fLC) activation. Ig-fLCs have been 
reported to bind to high affinity receptors on mast cells to induce 
degranulation upon second allergen encounter and an immedi-
ate allergic response (94). Interestingly, in a mast cell-dependent 
model for IBD, mice were sensitized with Ig-fLC followed by a rec-
tal hapten challenge, after which they displayed mucosal mast cell 
activation as well as increased vascular permeability (95). Patients 
suffering from IBD show strongly increased Ig-fLC concentrations 
in serum, as well as in colon and ileum tissue, suggesting a possible 
role for mast cells in IBD via Ig-fLC sensitization.
Due to the location of the inflammation, novel therapies focus 
on using dietary fiber and metabolites to treat (96) or prevent 
(97) symptoms of IBD (72, 98, 99), including mast cell activa-
tion or recruitment. Van Hung et al. (100) recently showed that 
fermentable dietary fiber (guar gum) could reduce inflammation 
in colitic mice, possibly through the reported increase in fecal 
SCFA concentrations. High-fiber intake and metabolite produc-
tion was inversely correlated with the loss of intestinal barrier 
function. Expression of pro-inflammatory cytokines, such as 
TNF, IL-6, and IL-17A, were downregulated due to the high-
fiber diet, although the specific source of these cytokines was not 
mentioned. Similar studies investigating the capacity of dietary 
fiber to reduce inflammation in colitis models have reported that 
the beneficial effects of dietary fiber in UC are not dependent on 
species (101) or model (102), nor on the type of dietary fiber (91).
Although similar effects can be found among the different kinds 
of dietary fiber, their fermentability varies per type, and with it, 
the location in the gut in which they might exert their beneficial 
effects. Indeed, a combination of two dietary fibers with different 
fermentation patterns (FOS and resistant starch) led to synergis-
tic prebiotic effects in colitis (103). These results can be translated 
into human studies, as supplementation with germinated barley 
foodstuff is able to reduce inflammation and improve the clinical 
activity index in UC patients (104, 105). Interestingly, fermenta-
tion of germinated barley foodstuff resulted in reduced colonic 
mast cell recruitment in colitic rats (106). The authors suggested 
that “the most probable mechanism responsible for the amelioration 
of DSS-induced colitis is the generation of SCFAs derived from 
germinated barley foodstuff.” Interestingly, administration of 
sodium butyrate to patients with distal UC indeed showed strong 
reduction of gut inflammation, although the role of mast cells in 
this context was not investigated (107). Since it is now known that 
mast cell activation can be inhibited by SCFAs in vitro as well as 
in vivo (55), the prediction that dietary fiber-derived SCFAs could 
regulate colitis via effects on mast cell activation seems plausible. 
Mast cells, dietary fiber, and its metabolites have thus established 
themselves as potential key modulators of inflammation in the 
large intestine, with the first signs of extensive interplay being 
reported (Table 2).
Studies regarding the effects of dietary fiber on colitis are 
relatively abundant, since microbial metabolites first become 
available at high concentrations in the proximal colon to exert 
potentially important effects on local health. Nonetheless, Mall 
et al. (120) recently reported that beta-glucan, a dietary fiber often 
found in oat and barley bran, strongly reduced mast cell-induced 
hyperpermeability of the ileum in patients with Crohn’s disease. 
In addition, they provided evidence that beta-glucan is partially 
able to inhibit in vitro mast cell activation, further strengthening 
the concept of a possible dietary fiber-metabolite-mast cell axis 
throughout the entire GI tract.
DieTARY FibeR iN MAST Cell-
ASSOCiATeD AiRwAY iNFlAMMATiON
Although limited in quantity, microbial metabolites remain 
key determinants in host–microbe mutualism outside of the 
intestinal tract, especially in well-perfused organs, such as the 
lungs. This was recently shown in a study by Halnes et al. (121), 
who reported that after ingestion of a meal high in soluble fiber 
(containing 3.5 g inulin and probiotics) the levels of neutrophils, 
macrophages, lymphocytes, IL-8, and eNO significantly decreased 
in the sputum of adults with stable asthma, as compared to the 
control group. Although a relatively small study, it reveals a 
potentially therapeutic effect of dietary fiber outside of the GI 
tract. This is in line with the general belief that a Mediterranean 
diet, typically high in fiber (due to fruits and vegetables) while 
low in saturated fats, can be a protective factor for wheezing and 
asthma (123, 124). Interestingly, patients with severe persistent 
asthma consume significantly less dietary fiber and more fat as 
compared to healthy controls (125).
The protective roll of dietary fiber in allergic airway diseases 
is further supported by mouse model studies, in which the effects 
of non-digestible oligosaccharides were tested on allergic airway 
inflammation and mast cell activation. Verheijden et al. reported 
that administration of GOS reduced house dust mite-driven 
allergic airway inflammation in mice, as measured by improved 
lung resistance, reduced cell numbers in bronchoalveolar lavage 
fluid (BALF), and lower cytokine production of lung homogen-
ates (126). These effects could be explained by a strong inhibition 
of mast cell degranulation as assessed by measuring the mast cell 
degranulation marker mMCP-1 levels in serum (126). Sagar et al. 
(110) found similar effects in a more chronic model for airway 
inflammation. A diet rich in GOS, FOS, and pectin-derived 
TAble 2 | Dietary fiber and metabolites in mast cell-associated diseases.
Food allergy Colitis/Crohn’s Allergic asthma Atopic dermatitis In vitro General health
Resistant 
oligosaccharides
↓ Allergic sensitization and 
symptoms in offspring (m) 
(78), ↓ acute hypersensitivity 
response (m) (80), ↓ diarrhea, 
hypothermia, and mucosal 
mast cell protease-1  
(mMCP-1) (m) (50)
↓ Allergic airway  
inflammation (108, 109) 
and serum mMCP-1 
(m) (110)
↓ Incidence of allergic 
manifestations 
(111–113), ↓ clinical 
symptom score (114), 
↓ plasma levels of total 
immunoglobulin E, IgG1, 
IgG2, IgG3 (115), and 
Ig-free L chain (116)
↓ Mouse mast 
cell degranulation 
directly (50, 108)
↑ SCFA production 
(7), ↑ galactin-9 
expression (m) (80)
(Sulfated) 
Polysaccarides
↓ Food allergy and 
anaphylaxis symptoms  
(m) (49)
↓ Sneezing, nasal 
rubbing, and airway 
hyperresponsiveness 
(m) (117)
↓ Antigen-induced 
mouse mast cell 
degranulation  
(48, 83) and cytokine 
production (m) (49)
↑ SCFA production 
(7, 118)
Pectin ↓ Allergic inflammation  
(m) (119)
↓ Allergen digestion 
by pepsin (64)
(Guar) Gum ↓ Peanut allergy (m), 
altered microbiome,  
↑ SCFA production (m) (79)
↓ Inflammation  
(m) (100)
↑ SCFA production 
(7, 100)
Resistant starch ↓ Inflammation (m), 
↑ intestinal barrier 
function (m) (103)
↑ SCFA production 
(7)
Germinated barley 
foodstuff
↓ Clinical scores 
(104,  105),  
↓ mast cell 
recruitment (r) (106)
↑ SCFA production 
(101)
Beta-glucan ↓ Mast cell-induced 
hyperpermeability of 
the ileum (120)
Inulin ↓ Neutrophils, macrophages, 
lymphocytes, IL-8, and eNO 
in the sputum (121)
Short-chain fatty 
acid (SCFA)
↓ Anaphylaxis (m) (79),  
↓ mast cell activation 
and inflammatory 
mediator content (p) (55)
↓ Gut inflammation 
(107)
↓ Clinical  
symptoms (m) (122),  
↑ hematopoiesis of 
common DC precursors 
and macrophage-DC 
precursors (m) (119)
↓ Mast cell 
degranulation and 
TNF-α production 
via Jun N-terminal 
kinase (52) or histone 
deacetylase (56)
m, in mouse; r, in rat; p, in pig.
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acidic oligosaccharides (with Bifidobacterium breve) was able to 
reduce airway inflammation, as measured by BALF-cell count 
and cytokine production in mice challenged with ovalbumin 
(OVA). Remarkably, treatment with a high-fiber diet strongly 
reduced serum mMCP-1 levels in allergic mice as compared to 
control mice, while a similar reduction in mMCP-1 levels was 
detected in BALF of mice receiving the high-fiber diet. Direct 
effects of oligosaccharides on regulation of mast cell activation 
and degranulation in the airways have also been reported. Chung 
et al. (108) investigated the effects of chitosan oligosaccharides, 
an oligomer of β-(1–4)-linked d-glucosamine, on both allergic 
airway inflammation as well as on RBL-2H3 degranulation and 
cytokine production. Effects of low-molecular weight chitosan 
oligosaccharides on in  vivo airway inflammation were consist-
ent with the results of the previously mentioned studies, but 
were unique in reporting a reduction of IgE–antigen complex- 
stimulated RBL-2H3 degranulation, as well as diminished 
cytokine production (IL-4, IL-13, and TNF-α).
Fewer studies have focused on the effects of dietary fiber and 
its metabolites on mast cell-associated upper airway inflamma-
tion, such as allergic rhinitis (AR). Most studies only investi-
gated possible correlations between Western (127, 128) and/or 
Mediterranean (129–131) diets and AR prevalence. Using a more 
mechanistic approach, Xie et  al. (117) reported that rats orally 
administered dietary fiber in the form of Cryptoporus polysac-
charides showed impaired symptoms of AR, including sneezing, 
nasal rubbing, and airway hyperresponsiveness. Wang et al. (122) 
directly administered sodium butyrate intranasally and found 
improved clinical symptoms in a mouse model of AR, most likely 
via HDAC inhibition.
Together, these studies implicate dietary fiber and metabolites 
as important regulators in the development and manifestation of 
allergic airway inflammation. Mast cells are essential facilitators 
of both upper and lower airway inflammation and have been 
shown to be under the direct influence of dietary fiber as well as 
its metabolites. Regulating mast cell activity via dietary fiber and 
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metabolites may, therefore, offer novel therapeutic strategies in 
the treatment allergic asthma and rhinitis (Table 2).
In addition to the effects on mast cell-associated diseases 
already described, a more indirect pathway of dietary metabolites 
shaping immune homeostasis has emerged. Trompette et al. (119) 
found that mice on a high-fiber diet (supplemented with 30% cel-
lulose or 30% pectin) showed significant differences in the ratio 
of Firmicutes to Bacteroidetes in their gut and lung microbiome. 
These mice also had increased levels of circulating SCFAs and 
were protected against allergic inflammation in the lung. Similar 
results were obtained in mice treated with the SCFA propionate 
(119). Remarkably, these effects were not associated with increased 
FoxP3 + CD25+ regulatory CD4+ T cells. In propionate-treated 
mice, recruitment of dendritic cells (DCs) and CD4+ T cells to 
the lung-draining lymph nodes was unaffected after 1–4 days. The 
activation state of these cells was similarly unaffected, with excep-
tions during the later stage of inflammation (day 4), suggesting 
that in this model the beneficial effects of propionate on airway 
inflammation are exerted by different means and/or cell types.
Elevated SCFAs concentrations were found in the circulation 
of high-fiber fed mice, but were undetectable in the lung, which 
could, at least in part, explain a lack of effects in the lung-draining 
lymph nodes themselves (119). Rather, SCFAs might influence 
hematopoiesis in the bloodstream and/or bone marrow. Trompette 
and colleagues reported that propionate treatment enhanced 
hematopoiesis of common DC precursors and macrophage-DC 
precursors, but did not mention any changes in hematopoietic 
differentiation of other cell types (119). Taken together, current 
evidence suggests that dietary fiber metabolites may influence 
allergic airway inflammation via altered immune cell differ-
entiation in bone marrow and/or blood circulation. Similar to 
DCs and macrophages, mast cell precursors originate from 
multipotent hematopoietic progenitor cells in the bone marrow, 
after which they enter the blood stream to mature in (mucosal) 
tissues (132, 133). This indicates that the effects of SCFAs on DCs 
and macrophages may translate to mast cell development and 
recruitment as well. Interestingly, it was recently reported that 
the administration of Bifidobacterium breve, a SCFA-producing 
bacteria strain (134), was able to regulate mast cell migration 
and activation in a mouse model of chronic allergic asthma 
(135). Interestingly, mast cells cultured from the bone marrow 
of mice receiving this SCFA-producing bacterial strain, displayed 
impaired IgE-mediated degranulation, which was not caused 
by reduced mast cell maturation (135). These data may indicate 
that microbial metabolites can influence mast cell migration and 
function via hematopoiesis in the bone marrow.
More research regarding the effects of dietary fiber and 
metabolites on mast cell activation in asthma is needed, including 
studying the possible effects of SCFAs on mast cell progenitors 
within this context.
ATOPiC DeRMATiTiS (AD)
Affecting up to 20% of children and up to 3% of adults in certain 
countries (136), AD is responsible for a significant social, health, 
and financial burden. Although a role for mast cells in AD has 
been established (137, 138), reports on the effects of dietary fiber 
and metabolites on skin inflammation have been divergent and 
sometimes even contradictory. Being located distant from the 
large intestine, the skin ordinarily contains neither high concen-
trations of dietary fiber nor its metabolites, making it an unlikely 
organ to be affected by gut microbial products. Nonetheless, there 
is emerging evidence suggesting that high-fiber diets can help to 
prevent and treat AD in mice and young infants, although the 
mechanism of this effect requires further investigation. AD is 
 typically diagnosed in (very) young infants and considered the 
first manifestation of the atopic march (139). Studies investigating 
the effects of dietary fiber on AD, therefore, mainly use scGOS/
lcFOS resembling non-digestible oligosaccharides in human 
milk, often the first type of diet young infants receive.
Arslanoglu and colleagues (111) studied the protective effects 
of scGOS/lcFOS supplementation in young infants with parental 
history of atopy and assessed the incidence of allergic manifesta-
tions during 2  years. Within this period, children receiving the 
scGOS/lcFOS supplementation had significantly lower incidence 
of allergic manifestations, including AD. They also reported a 
decline in recurrent wheezing and allergic urticaria, in addition 
to fewer respiratory tract infections, fever episodes, and antibiotic 
prescriptions. Interestingly, most of these beneficial health effects 
persisted until the age of five, as reported in their follow-up study 
(112). Grüber et al. showed a similar decrease in AD prevalence in 
low-atopy-risk children, in a somewhat larger study (>300) (113). 
Using only fructo-oligosaccharide for the treatment of AD was also 
shown to be effective (114). The AD symptom score (SCORAD) was 
significantly lower following administration of Kestose, a fructo-
oligosaccharide, for 12 weeks. An interesting study by van Hoffen 
et al. showed that GOS/FOS supplementation in young infants could 
lead to a significant reduction in plasma levels of total IgE, IgG1, 
IgG2, and IgG3, but not IgG4 (115). These data suggest that GOS/
FOS supplementation induces a beneficial antibody profile, poten-
tially modulating the outcome of allergic manifestations later in life.
Although concentrations of Ig-fLC are often not measured, 
they are significantly associated with allergic and non-atopic 
rhinitis, asthma, food allergy, and colitis (95, 140, 141). In line 
with previous reports, Schouten et al. found that plasma levels 
of Ig-fLC were elevated in patients with AD, but for the first 
time showed attenuated Ig-fLC production in young infants at 
risk receiving a scGOS/lcFOS mixture (116). This represents a 
potentially important finding for patients suffering from mast 
cell-associated diseases, since Ig-fLCs have been shown to induce 
mast cell activation (as described above) (94).
In summary, these studies suggest that dietary fiber may 
influence the development and manifestation of AD in patients, 
although further research into the precise role of mast cells in this 
context is required. Last, it should not go without mentioning that 
intervention diets based on oligosaccharide supplementation, 
administered to young infants, do not always succeed in either 
treatment (142) or prevention (143, 144) of AD.
CONClUDiNG ReMARKS AND FUTURe 
PeRSPeCTiveS
Mast cells have been shown to play a crucial role in the mani-
festation of allergic and non-allergic diseases. Many of these 
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mast cell-associated diseases exhibit a significant increase in 
prevalence on a global scale, closely following the development 
of industrialization and improved living conditions. Dietary 
fiber and its metabolites are thought to play an important role in 
the development and manifestation of these diseases, as recent 
research has provided evidence of significant health benefits of 
dietary fiber and its metabolites in the prevention and treatment 
of mast cell-associated diseases.
Here, we have summarized the known effects of these dietary 
fibers and metabolites on mast cell activation in vitro and in vivo 
(Table 2). Consistent with the reported health benefits on other 
immune cells (145), dietary fiber (especially polysaccharides and 
oligosaccharides) and metabolites (SCFAs) can regulate mast cell 
function. Mast cell activation can be downregulated by pretreat-
ment with these substances, via inhibition of various components 
of the MAPK signaling pathway and a subsequent reduction in 
transcription factor activity. Furthermore, both butyrate and the 
activation of the MAPK signaling pathway can induce chromatin 
modifications via the regulation of HDAC activity and its intra-
cellular localization. In addition, diets high in fiber can prevent 
sensitization of mast cells either by inhibiting allergen digestion 
or by upregulating galactin-9 expression in mice, thus blocking 
the formation of IgE–antigen complexes.
Although these results are promising and may provide new 
insights regarding novel approaches to target mast cell function, 
certain key mechanisms mediating the inhibitory effects on mast 
cells remain unclear. Inhibition of late-phase mast cell activation 
by dietary fiber and butyrate, characterized by reduced mediator 
synthesis and secretion, can be explained by their effects on MAPK 
phosphorylation and transcription factor activity. However, 
modulation of these pathways by dietary components cannot 
account for all of the inhibitory effects observed with mast cell 
degranulation. The cascade leading up to mast cell degranulation 
is a complex process upstream of MAPK signaling, mainly involv-
ing PLCγ and PKC activation followed by an increase in calcium 
mobilization. Indeed, mast cell degranulation is not known to 
be affected by inhibition of the MAPK signaling pathway (39). 
Possible alternative mechanisms could involve modifications of 
the mast cell proteome and epigenome by dietary components 
(e.g., by promoting acetylation). Since butyrate is a potent HDAC 
inhibitor, it could impact many key gene regulatory processes 
modulating mast cell activity through histone acetylation, includ-
ing transcription factor binding and transcription activation. 
Potential therapeutic implications of butyrate-induced epigenome 
modifications have been described (141), but no direct link of 
such therapeutic effects with regulation of mast cell function has 
been established. The de novo synthesis of new proteins may not 
be required, as the functions of the expressed proteins in the cell 
could be readily modified by butyrate-regulated HDACs and 
post-translational acetylation is known to regulate protein func-
tion (61). However, the effects of non-histone protein acetylation 
on mast cell function remain unclear.
Finally, dietary fiber and its metabolites may exert their effects 
on mast cells in an indirect manner. Very recently, the function 
of other immune cells, such as group 2 innate lymphoid cells 
(ILC2s), have shown to be subject to the effects of butyrate (146). 
Cell activation, local cytokine production, and secretion as well as 
cell to cell contact with/by other immune cells can modulate mast 
cell responses (147). Therefore, butyrate may regulate mast cell 
function indirectly via secondary pathways as well, e.g., via IL-9-
producing ILC2s (148). Taken together, mast cell function has 
been shown to be susceptible to the immunoregulatory effects of 
dietary fiber and butyrate. Further understanding of the mecha-
nisms by which dietary fiber and butyrate can regulate mast cell 
activation may help in the future development of novel approaches 
for the prevention and treatment of mast cell-associated diseases.
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